Details for Patent: 10,278,969

Which drugs does patent 10,278,969 protect, and when does it expire?

Patent 10,278,969 protects TRUSELTIQ and is included in one NDA.

This patent has forty-three patent family members in thirty-two countries.

Summary for Patent: 10,278,969

Title:	Pharmaceutical dosage forms
Abstract:	The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
Inventor(s):	Ribeiro; Suzie (Basel, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	15/102,378
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 10,278,969

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		DISCN	Yes	No			Y
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 10,278,969

PCT Information
PCT Filed	December 11, 2014	PCT Application Number:	PCT/IB2014/066820
PCT Publication Date:	June 18, 2015	PCT Publication Number:	WO2015/087283

International Family Members for US Patent 10,278,969

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	098716
Australia	2014362999
Canada	2930055